determin
etiolog
agent
bronchoalveolar
lavtract
infect
lrti
promot
target
therapi
prevent
unnecessari
investig
antimicrobi
hospit
compar
detect
sputum
detect
pathogen
lower
tract
thought
higher
specif
typic
bacteri
pathogen
higher
sensit
atyp
pathogen
pneumocysti
jiroveci
mycobacterium
speci
cytomegaloviru
bartlett
et
al
advantag
less
clear
detect
respiratori
virus
mycoplasma
pneumonia
mp
chlamydophila
pneumonia
cp
convent
method
pathogen
detect
includ
antigen
detect
method
tradit
viral
cultur
tvc
usual
allow
identif
newli
identifi
viral
pathogen
human
metapneumoviru
hmpv
van
den
hoogen
et
al
human
coronavirus
hcov
fouchier
et
al
nucleic
acid
amplif
test
nat
use
rapidli
detect
virus
mp
cp
nasopharyng
sampl
np
patient
lrti
grondahl
et
al
michelow
et
al
miyashita
et
al
may
sensit
convent
method
especi
mp
cp
miyashita
et
al
primari
object
studi
determin
routin
addit
nat
multipl
respiratori
virus
mp
cp
diagnost
investig
bronchoalveolar
lavag
bal
endotrach
tube
ett
sampl
would
detect
signific
number
pathogen
miss
convent
method
secondari
object
determin
test
convent
nat
method
would
yield
discord
result
multipl
sampl
submit
day
convent
test
perform
per
submitt
request
direct
fluoresc
antibodi
dfa
test
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
influenza
flu
b
flu
b
imagen
tm
dakocytom
ltd
perform
rapid
respiratori
cultur
rrc
mix
cell
line
mink
lung
nci
immunofluoresc
stain
light
diagnost
tm
chemicon
intern
plate
format
lee
et
al
huang
turchek
avail
octob
juli
perform
dfa
test
neg
request
posit
piv
confirm
posit
piv
dfa
tvc
use
standard
cell
line
rhesu
monkey
kidney
cell
set
throughout
studi
unless
viru
alreadi
detect
dfa
rrc
cultur
mp
perform
use
respiratori
mycoplasma
agar
plate
biphas
media
respiratori
mycoplasma
agar
respiratori
glucos
broth
sampl
aliquot
store
nat
prepar
extract
respiratori
specimen
util
nuclisen
autom
isol
reagent
extractor
accord
manufactur
instruct
stlaurent
canada
ml
specimen
extract
elut
volum
ml
boom
et
al
threshold
cycl
number
realtim
pcr
assay
cutoff
posit
specimen
realtim
nasba
defin
base
experi
use
known
posit
neg
cultur
control
clinic
specimen
maxim
sensit
without
compromis
specif
data
method
valid
alreadi
publish
samuelson
et
al
fox
et
al
fox
hibbitt
et
al
welti
et
al
moor
et
al
moor
et
al
addit
experi
undertaken
valid
set
phase
studi
ensur
consist
perform
publish
assay
defin
paramet
new
method
posit
result
assay
determin
assess
threshold
cycl
number
target
similar
way
describ
previous
welti
et
al
fortyf
cycl
run
assay
signific
increas
signal
background
togeth
typic
amplif
curv
use
delin
specimen
posit
target
question
specif
assay
confirm
use
sampl
high
titer
respiratori
virus
bacteria
well
align
sequenc
data
use
specif
probe
assay
data
shown
end
point
sensit
assay
either
defin
culturebas
procedur
flua
flub
rsv
adenoviru
rhinoviru
rv
mp
cp
clone
target
sequenc
end
point
determin
use
dna
plasmid
coronavirus
synthet
transcrib
rna
hmpv
accept
sensit
input
titrat
virus
copi
input
plasmid
clone
dna
transcrib
rna
cfu
input
bacteria
optim
new
assay
qualiti
control
publish
method
contamin
minim
use
separ
area
clean
master
mix
prepar
extract
prepar
specimen
control
set
nat
control
taken
throughout
step
procedur
ensur
problem
relat
possibl
contamin
would
identifi
result
disregard
amplif
nasba
flu
flu
b
piv
rsv
rv
amplif
detect
inhous
develop
realtim
nasba
similar
describ
previous
fox
hibbitt
et
al
moor
et
al
moor
et
al
press
samuelson
et
al
five
differ
nasba
reaction
set
target
flu
flu
b
singl
reaction
tube
piv
second
tube
piv
third
tube
rsv
b
fourth
reaction
rv
fifth
rv
posit
specimen
test
enterovirusspecif
nasba
ensur
specif
rv
nasba
crossreact
relat
nonrhinoviru
picornavirus
high
copi
number
nasba
molecular
beacon
probe
use
fluorescein
fam
label
nonfluoresc
quencher
dimethylaminophenylazo
benzoic
acid
dabcyl
end
posit
reaction
first
screen
follow
repeat
test
monoplex
format
differenti
posit
target
multiplex
assay
primer
probe
realtim
nasba
either
describ
previous
hibbitt
fox
hibbitt
et
al
moor
et
al
adapt
realtim
format
previou
studi
samuelson
et
al
yet
publish
format
assay
flu
b
rsv
primer
probe
previous
publish
adapt
studi
given
tabl
ii
rhinoviru
molecular
beacon
rna
polymeras
tailspac
region
primer
stem
region
molecular
beacon
given
ital
rsv
respiratori
syncyti
viru
target
amplif
nucleoprotein
flu
polymeras
flu
b
hemagglutininneuraminidas
phosphoprotein
fusion
protein
rsv
b
noncod
region
rv
amplif
detect
nasba
product
util
nuclisen
easyq
analys
ml
templat
input
case
describ
previous
moor
et
al
appropri
posit
neg
control
includ
assay
clinic
sampl
test
optim
reaction
condit
cut
valu
posit
result
set
neg
control
wild
type
signal
chain
reaction
pcr
five
differ
realtim
pcr
assay
set
complet
rang
respiratori
pathogen
investig
studi
assay
hmpv
adv
hcov
design
hous
util
hydrolysi
probe
taqman
chemistri
amplif
analysi
abi
appli
biosystem
abi
foster
citi
ca
primer
probe
design
hous
assay
util
primer
express
softwar
abi
hcov
hmpv
assay
design
incorpor
use
black
hole
quencher
end
hydrolysi
probe
wherea
adv
assay
design
util
tamara
quencherlabel
target
hous
realtim
pcr
assay
fusion
protein
hmpv
hexon
protein
adv
spike
protein
separ
primer
probe
replicas
addit
target
newli
design
realtim
pcr
assay
util
multipl
primer
probe
requir
ensur
pick
known
sequenc
variant
tabl
standard
twostep
random
cdna
rtpcr
protocol
univers
condit
thermocycl
profil
use
detect
hcov
hmpv
abi
reagent
assay
hmpv
adv
util
fam
report
label
singlegen
target
assay
virus
run
multiplex
assay
differ
label
fam
vic
differenti
group
virus
virus
detect
primer
spike
gene
replicas
gene
fam
labeledprob
inhous
design
adv
assay
run
univers
cycl
condit
abi
alongsid
hous
assay
cdna
stage
addit
hous
develop
realtim
pcr
assay
describ
multiplex
assay
cp
mp
undertaken
use
previous
describ
primer
probe
procedur
welti
et
al
appropri
posit
neg
control
includ
assay
age
patient
hospit
statu
histori
transplant
underli
malign
record
bal
ett
sampl
submit
studi
suffici
volum
attempt
nucleic
acid
extract
one
nat
perform
bal
ett
sampl
femal
male
adult
median
year
rang
year
children
year
age
median
year
rang
year
fig
time
sampl
obtain
patient
outpati
n
admit
adult
intens
care
unit
icu
n
adult
neurosurg
icu
n
adult
thoraciccardiac
surgic
icu
ward
n
intern
medicin
ward
n
pediatr
ward
n
pediatr
neonat
icu
n
tradit
respiratori
viru
test
perform
sampl
respiratori
virus
detect
dfa
rrc
tvc
inpati
outpati
sampl
sampl
collect
differ
patient
tabl
iii
one
patient
viru
detect
three
sampl
submit
day
piv
anoth
patient
two
differ
virus
rsv
dfa
piv
rrc
respect
identifi
two
sampl
submit
one
day
apart
two
patient
differ
virus
detect
sampl
collect
day
adv
piv
day
piv
flu
apart
antigen
detect
least
one
viru
perform
sampl
posit
sampl
rrc
perform
sampl
detect
virus
sampl
tvc
perform
sampl
detect
virus
sampl
cultur
posit
mp
sampl
sampl
collect
bal
day
pediatr
oncolog
inpati
coinfect
detect
convent
method
insuffici
nucleic
acid
sampl
test
nat
target
fig
sampl
test
posit
sampl
test
target
test
posit
total
sampl
differ
patient
test
posit
pathogen
nat
sampl
test
posit
one
target
flu
flu
b
rsv
adv
rv
hmpv
hcov
hcov
hcov
mp
cp
test
posit
two
target
adv
rv
one
flu
adv
adv
rsv
adv
rsv
fifti
sampl
posit
nat
result
collect
inpati
sampl
outpati
result
convent
method
detect
sampl
test
posit
nat
flu
piv
rsv
adv
mp
shown
tabl
iv
sampl
pathogen
detect
convent
method
test
posit
pathogen
nat
second
pathogen
identifi
nat
sampl
anoth
five
sampl
test
neg
nat
posit
convent
method
piv
n
one
detect
rrc
one
tvc
rsv
n
detect
dfa
adv
n
detect
tvc
child
mention
rsv
dfa
piv
rrc
one
day
apart
patient
sameday
sampl
bal
sampl
ett
sampl
sampl
process
convent
method
fortyeight
patient
pathogen
detect
convent
method
patient
pathogen
detect
sampl
piv
three
sampl
mp
two
sampl
respect
patient
neg
posit
result
pathogen
differ
sampl
sameday
sampl
patient
posit
piv
adv
respect
patient
nat
perform
sameday
sampl
pathogen
detect
nat
pathogen
detect
nat
one
sampl
insuffici
volum
nat
sampl
pathogen
detect
nat
sampl
neg
posit
result
nat
pathogen
differ
sampl
one
three
sampl
test
posit
piv
one
patient
one
two
sampl
test
posit
rv
one
patient
one
two
sampl
test
posit
adv
two
patient
one
also
test
posit
piv
monthli
distribut
sampl
pathogen
detect
shown
figur
sourc
sampl
shown
tabl
v
posit
sampl
exclud
sampl
taken
day
apart
concord
result
come
immunocompromis
host
appar
relationship
sourc
sampl
pathogen
detect
isol
viru
week
month
apart
occur
four
solid
organ
transplant
patient
two
children
tracheostomi
studi
demonstr
addit
nat
respiratori
virus
mp
cp
convent
j
med
virol
doi
test
perform
submitt
request
lower
respiratori
tract
specimen
increas
detect
rate
potenti
pathogen
increas
yield
mainli
attribut
detect
pathogen
usual
detect
convent
method
rv
hmpv
hcov
hcov
hcov
increas
detect
flu
piv
rsv
especi
adv
also
appar
previou
studi
compar
nat
convent
method
detect
respiratori
virus
consist
demonstr
increas
yield
nat
akhtar
et
al
van
elden
et
al
ison
et
al
garbino
et
al
legoff
et
al
van
kraaij
et
al
optim
convent
techniqu
use
studi
current
report
virus
detect
convent
method
occasion
detect
nat
garbino
et
al
detect
mp
cp
lrti
difficult
sensit
cultur
poor
yield
nat
low
current
studi
previou
studi
show
yield
mp
nat
higher
sputum
throat
swab
np
specimen
rati
et
al
suggest
type
sampl
import
studi
need
compar
nat
result
lower
versu
upper
respiratori
tract
sampl
clinic
signific
virus
detect
nat
respiratori
sampl
establish
previou
studi
normal
host
shed
piv
detect
tvc
usual
occur
day
sometim
persist
month
muchmor
et
al
shed
adv
occur
mean
day
persist
day
larranaga
et
al
shed
mp
could
still
document
cultur
half
patient
week
acut
infect
foy
et
al
nat
detect
much
lower
concentr
pathogen
shed
pathogen
detect
longer
period
time
convent
method
van
kraaij
et
al
pathogen
potenti
detect
patient
remot
infect
patient
nonviabl
pathogen
evid
detect
respiratori
virus
nat
alway
clinic
signific
asymptomat
children
picornavirus
detect
nat
np
sampl
children
asthma
remain
posit
picornavirus
nat
week
acut
asthma
exacerb
correl
persist
viru
symptom
jartti
et
al
less
evid
asymptomat
shed
respiratori
virus
even
shed
occur
clinic
signific
pathogen
detect
nat
may
greater
lower
upper
respiratori
tract
sampl
expect
incid
asymptomat
shed
lower
tract
less
nat
multipl
respiratori
viral
target
neg
bal
ventil
children
akhtar
et
al
adult
evid
lrti
garbino
et
al
suggest
asymptomat
shed
virus
lower
tract
common
lower
respiratori
tract
sampl
patient
count
repeat
sampl
posit
pathogen
within
period
n
addit
sampl
patient
count
differ
virus
n
addit
sampl
patient
viru
day
apart
n
addit
sampl
patient
episod
viru
occur
week
apart
flu
month
apart
month
apart
adv
month
apart
rv
solid
organ
transplant
patient
month
apart
rv
pediatr
patient
tracheostomi
four
patient
virus
detect
convent
method
neg
nat
exclud
tabl
one
patient
piv
detect
nat
subsequ
day
posit
dfa
piv
one
day
rsv
subsequ
day
classifi
piv
tabl
includ
one
oncolog
patient
use
nat
increas
chanc
recogn
coinfect
previou
small
retrospect
studi
demonstr
half
children
admit
icu
rsv
hmpv
coinfect
greensil
et
al
konig
et
al
sempl
et
al
prospect
studi
rate
appear
much
lower
children
less
sever
diseas
robinson
et
al
eight
patient
current
studi
one
viru
identifi
prospect
studi
would
requir
determin
clinic
signific
viral
coinfect
identifi
nat
role
differ
respiratori
virus
play
risk
factor
secondari
bacteri
pneumonia
yield
respiratori
virus
nat
higher
bal
induc
sputum
pair
nasal
wash
nasalthroat
swab
four
previou
studi
seemung
et
al
rohd
et
al
sempl
et
al
van
kraaij
et
al
equival
one
studi
van
elden
et
al
yield
mp
higher
bal
throat
swab
one
small
studi
falguera
et
al
howev
risk
invas
procedur
may
outweigh
benefit
increas
yield
lower
tract
sampl
especi
difficult
obtain
children
given
virus
detect
sampl
viral
detect
request
like
costeffect
routin
nat
multipl
pathogen
lower
respiratori
tract
sampl
submit
microbiolog
studi
howev
nat
allow
detect
pathogen
almost
sampl
submitt
request
convent
viral
test
result
test
neg
may
costeffect
routin
perform
nat
multipl
pathogen
sampl
submitt
request
viral
detect
sampl
submit
day
total
sampl
came
bal
half
sampl
pathogen
detect
discord
result
suggest
test
one
bal
sampl
day
warrant
one
limit
studi
ascertain
patient
bal
ett
sampl
submit
viral
studi
clinic
evid
lrti
may
explain
rate
detect
pathogen
lower
previou
nat
studi
akhtar
et
al
van
elden
et
al
ison
et
al
garbino
et
al
van
kraaij
et
al
possibl
undertak
confirmatori
test
nat
due
limit
amount
origin
materi
extract
avail
design
assay
base
avail
sequenc
specif
check
undertaken
possibl
correl
convent
method
ensur
valid
result
conclus
addit
nat
test
potenti
respiratori
pathogen
provid
diagnost
inform
could
alter
medic
manag
patient
howev
possibl
goal
could
achiev
optim
use
convent
method
detect
respiratori
pathogen
futur
studi
compar
result
lower
respiratori
tract
sampl
obtain
upper
respiratori
tract
sampl
determin
advantag
obtain
invas
lower
tract
sampl
prospect
compar
outcom
patient
presenc
absenc
nat
test
